ObsEva SA.

NASDAQ:OBSV   3:59:53 PM EDT
1.74
+0.07 (+4.19%)
Products, Regulatory

Obseva Announces Additional Efficacy Results For Linzagolix 200 Mg With Add-Back Therapy And Linzagolix 75 Mg Without Abt In Phase 3 Edelweiss 3 Trial In Patients With Moderate-To-Severe Endomet

Published: 03/22/2022 11:52 GMT
ObsEva SA. (OBSV) - Obseva Announces Additional Efficacy Results for Linzagolix 200 Mg With Add-back Therapy (abt) and Linzagolix 75 Mg Without Abt in the Phase 3 Edelweiss 3 Trial in Patients With Moderate-to-severe Endometriosis-associated Pain.
Obseva Sa - Results From Post-treatment Follow-up of Edelweiss 3 Are Expected in Early 3q2022.
Obseva Sa - Results From Treatment Phase of Extension Study and Post-treatment Follow-up Phase Expected in Early 3q2022 and 4q2022, Respectively.
Obseva Sa - Reductions in Co-primary Efficacy Endpoints, Compared to Placebo Observed for Both Doses After 1 & 2 Months of Treatment, Respectively.